Weikang Bio-Technology, a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), western prescription and OTC pharmaceuticals and other health and nutritional products in China, announced that it has engaged RedChip Companies to lead its public and investor relations efforts. Yin Wang, Chairman and CEO of Weikang stated, "We selected RedChip based on their proven track record of increasing investor awareness for emerging growth companies, as well as their international presence and innovative multimedia platform of products and services. We are confident that RedChip will help us attract new investors while strengthening our relationships with current shareholders." "We are pleased to have the opportunity to represent Weikang," said Mr Dave Gentry, President of RedChip Companies "China is expected to become the world's third-largest pharmaceutical market by 2020, with market growth driven by national healthcare reform initiatives and a rapidly aging population. Weikang has an impressive portfolio of high-margin pharmaceutical and nutritional products and has achieved strong revenue and net income growth in recent years. We look forward to implementing a comprehensive investor and media relations program and introducing them to our investor network."